ALMo: Interactive Aim-Limit-Defined, Multi-Objective System for Personalized High-Dose-Rate Brachytherapy Treatment Planning and Visualization for Cervical Cancer

Abstract: In complex clinical decision-making, clinicians must often track a variety of competing metrics defined by aim (ideal) and limit (strict) thresholds. Sifting through these high-dimensional tradeoffs to infer the optimal patient-specific strategy is cognitively demanding and historically prone to variability. In this paper, we address this challenge within the context of High-Dose-Rate (HDR) brachytherapy for cervical cancer, where planning requires strictly managing radiation hot spots while balancing tumor coverage against organ sparing. We present ALMo (Aim-Limit-defined Multi-Objective system), an interactive decision support system designed to infer and operationalize clinician intent. ALMo employs a novel optimization framework that minimizes manual input through automated parameter setup and enables flexible control over toxicity risks. Crucially, the system allows clinicians to navigate the Pareto surface of dosimetric tradeoffs by directly manipulating intuitive aim and limit values. In a retrospective evaluation of 25 clinical cases, ALMo generated treatment plans that consistently met or exceeded manual planning quality, with 65% of cases demonstrating dosimetric improvements. Furthermore, the system significantly enhanced efficiency, reducing average planning time to approximately 17 minutes, compared to the conventional 30-60 minutes. While validated in brachytherapy, ALMo demonstrates a generalized framework for streamlining interaction in multi-criteria clinical decision-making.

• The paper introduces ALMo, an aim-limit interface and constrained multi-objective optimizer that lets clinicians balance tumor coverage, organ-at-risk doses, and tissue hot spots interactively.
• ALMo produced clinically acceptable plans in 100% of 25 retrospective cases, improved dosimetric quality over manual plans in 65% of cases, and averaged 17.6 minutes per planning session.
• The system’s explicit hot-spot constraints outperformed the PNaV baseline, while robust plan selection reached about 95% of maximum hypervolume 14 times faster than exhaustive search.

ALMo is an interactive decision support system for high-dose-rate (HDR) brachytherapy treatment planning in cervical cancer, built around a clinically intuitive "aim-limit" interface that lets clinicians navigate the Pareto surface of dosimetric trade-offs by directly manipulating soft (ideal) and hard (strict) thresholds. The system integrates a three-stage pipeline—automated parameter setup, constrained multi-objective plan optimization with explicit toxicity control, and iterative clinician exploration—and was validated retrospectively on 25 clinical cases. The headline results are that ALMo produced plans with no major clinical deficiencies in 100% of evaluated cases, improved dosimetrics over manually created plans in 65% of cases, and reduced average end-to-end planning time to approximately 17.6 minutes against a conventional 30–90 minutes.

Clinical context and problem formulation

HDR brachytherapy for cervical cancer must be planned intraoperatively while the patient is under anesthesia with applicators in place, so planning duration directly correlates with anesthesia exposure and positional uncertainty. The optimization problem is defined over a set of CT-derived structures—PTV, OARs (bladder, rectum, bowel)—with dwell times $t$ and a dose-rate matrix $G$ computed under the TG-43 formalism, such that $d = Gt$. Because standard dose-volume-histogram (DVH) metrics such as $\text{PTV}_{V700}$ and $\text{Bladder}_{D2cc}$ are non-convex, the authors adopt truncated conditional value-at-risk (TCVaR) approximations, which require a reference dose distribution and a contracting-window iteration to identify the voxels to truncate. The prescription dose is 700 cGy, and hot spots are defined as regions receiving 200% of prescription.

Positioning relative to prior work

The paper situates ALMo against three research threads. Interactive Pareto-navigation tools such as PNaV enable exploration across a 30% dose range but require substantial manual parameter setup and exclude hot-spot metrics entirely—a deficiency the authors demonstrate empirically to be clinically decisive. Automated preference-learning approaches, including inverse optimization and bilevel objective selection, reduce planning burden but require large training corpora and may not transfer across institutions. Deep learning dose-prediction methods generate achievable dose distributions but do not support interactive trade-off exploration; the authors argue ALMo's constrained, controllable formulation is a substantive advantage over learned predictors. The most distinctive contribution relative to all of these is explicit control of toxicity hot spots in the cervical mucosa, vaginal mucosa, and perineedle regions, which the authors note is achieved without the combinatorial explosion of penalty weights that typically makes such constraints intractable.

The ALMo pipeline

Plan optimization. The core optimizer is an $\epsilon$-constraint multi-objective linear program: it maximizes PTV coverage (low-dose-tail TCVaR $\theta_1^-$) subject to upper bounds on high-dose-tail TCVaR $\theta_k^+$ for all other structures. Hot spot regions (HSRs) are handled by constructing artificial structures: a ring of voxels within a fixed distance of the PTV contour is split into vaginal mucosa (hottest 18% under ovoid-only loading) and cervical-region structures, and perineedle regions are defined as voxels within a small distance of needle dwell positions. These artificial structures enter the constraint set directly, giving fine-grained control over toxicity in sensitive tissue.

Iterative clinician exploration. Clinician aim and limit values are translated into soft-hard utility functions (SHFs), which map metric values below limits to $-\infty$, reward movement toward aims, and saturate beyond a saturation point $$\alpha^\tau = \alpha^{lim} + \zeta(\alpha^{aim} - \alpha^{lim})$$ with $G$0. Because the clinician's true preference vector $G$1 is unknown, ALMo returns a small, robustly representative set of plans $G$2 ($G$3) by solving a robust submodular observation selection problem: maximize, over subsets of size $G$4, the worst-case ratio of achieved utility to the best achievable under any $G$5. The two-step MoSH procedure first densely samples the aim-limit region (with a coarse grid search plus piecewise-linear interpolation warm start) and then sparsifies via a greedy partial-cover algorithm with a logarithmic approximation guarantee. Slider adjustments are further interpreted as implicit rankings over displayed plans and incorporated into a Bayesian posterior over $G$6 using a mixture of Plackett-Luce likelihoods, weighted by the magnitude of each bound adjustment.

Visualization. The system provides parallel-coordinates and tabular views of the global trade-off surface, and ALMo-Viz-Explain, a local visualization grid showing canonical axial, sagittal, and coronal planes plus axial slices of peak-dose regions in each HSR, designed to allow plan assessment without switching to commercial systems.

Automated setup. Three algorithms remove manual initialization. The reference plan initialization algorithm performs a coordinate-wise search over HSR multipliers with voxel-wise dose constraints until an OAR aim is first violated, simultaneously yielding the reference dose distribution and identifying the limiting organ. The limiting organs prediction algorithm restricts the expensive grid search to HSRs plus the limiting OARs. The epsilon-ratio method derives the TCVaR constraint values corresponding to desired DVH aim and limit values, iteratively refined until estimates fall within tolerance. The authors emphasize that the initialization need only be approximately correct because the subsequent epsilon-ratio refinement recovers granularity—a deliberate division of labor between a fast coarse stage and a tunable refinement stage.

Results

Plan quality. On 20 retrospective cases, using a clinician-devised four-grade rubric, plans generated by the ALMo optimizer received Grade 0 (major improvement over clinical plan) in 3 cases and Grade 1 (minor improvement) in 10, with 7 Grade 2 and no Grade 3 plans. The PNaV baseline, which lacks hot-spot control, received Grade 3 in 18 of 20 cases—primarily due to 200%-of-prescription hot spots in the vaginal mucosa and absent pear-shaped dose distributions. This is the paper's strongest contrast and directly supports the claim that explicit HSR constraints are necessary, not merely beneficial, for clinically viable cervical brachytherapy plans.

End-to-end planning. On five additional cases with three iterative exploration trials each, the best plan per trial received Grade 1 in 3 cases and Grade 2 in 2, again with no Grade 3, at a mean planning time of 17.6 ± 1.7 minutes. The authors are appropriately careful that these are retrospective trials conducted by the development team rather than live intraoperative use by independent clinicians.

Exploration efficiency. Against an exhaustive grid search over the refined parameter space, the MoSH-based sampler reaches approximately 95% of the maximum hypervolume (computed with respect to the clinician's limit values) 14× faster in wall-clock time, averaged across the five cases. The limiting organs prediction algorithm achieved 100% accuracy in 31.6 seconds on average, roughly 85% faster than the earliest point at which the baseline grid search reached full accuracy. The epsilon-ratio method's estimates deviate from target DVH values by at most about 8%, with a consistent negative skew that the authors argue is clinically benign because the binding constraint is typically a single OAR (most often the bladder) that the method characterizes accurately.

Visualization. Across 15 evaluated plans, external software was needed for only 5; ALMo-Viz-Explain alone sufficed for assessment in 66.7% of iterations. Qualitatively, it was most effective for rapid rejection of non-viable plans, with viable plans still receiving secondary review in conventional software—a sensible safety-conservative usage pattern.

Limitations and open questions

The paper concedes several constraints on its claims. The evaluation is retrospective and conducted by the system's developers; the reported 17-minute planning times have not been validated in live intraoperative settings, where user proficiency curves and institutional workflow variability could erode the gains. ALMo is a planning optimizer rather than an end-to-end platform: it excludes automated segmentation upstream and physical quality assurance downstream. The reference plan initialization uses deliberately coarse multiplier granularity to meet time constraints, yielding lower initial utility for bladder and rectum—a trade-off the authors leave as a configurable clinical choice rather than resolving. The preference-learning mechanism assumes that slider adjustments can be mapped to meaningful implicit rankings, an assumption inherited from prior work and not independently validated here. Open questions include whether the aim-limit interaction model generalizes across clinicians with divergent preferences, and whether the HSR construction heuristics (ring distance, 18% hottest-voxel split, ovoid-only initialization) transfer to patients with atypical applicator geometry.

Conclusion

ALMo demonstrates that an aim-limit-defined interface, combined with constrained multi-objective optimization that explicitly controls mucosal and perineedle hot spots, can match or exceed manually planned HDR brachytherapy quality while roughly halving planning time. The comparison against PNaV provides a clear empirical case that hot-spot constraints are indispensable in this domain, and the robust submodular selection framework offers a principled mechanism for presenting sparse, preference-robust plan sets. The principal caveat is that all evidence is retrospective; confirmation under live intraoperative conditions, and extension to other treatment sites, remain unresolved.